Save on Sotorasib with Coupons, Discounts & Savings Programs

Sotorasib is available as a 120 mg and 320 mg oral tablet.

Sotorasib is a KRAS G12C inhibitor and is used to treat metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment.

Sotorasib is a KRAS G12C inhibitor. KRAS is a protein in your body that sends signals to your cells to grow and divide. In certain lung cancers, a mutation (change) in KRAS called G12C leads to uncontrolled cell growth. Sotorasib attaches to KRAS proteins with the G12C mutation. By doing so, the medication helps block tumor growth.

The typical dose is 960 mg by mouth once a day, with or without food. Sotorasib is available as 120 mg and 320 mg tablets. The daily dose is taken as eight 120 mg tablets or three 320 mg tablets at one time each day.

Sotorasib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Sotorasib:

• Diarrhea
• Muscle or bone pain
• Fatigue
• Nausea
• Cough

Serious side effects are rare with Sotorasib. Contact your healthcare provider immediately if you experience any of the following.

• Liver injury: pain in the right side of the stomach, yellowing of the eyes or skin, dark or brown urine
• Lung damage: cough, shortness of breath, fever

The following medications may interact with Sotorasib:

• Coadministration of Sotorasib with gastric acid-reducing agents decreased Sotorasib concentrations which may reduce the efficacy of Sotorasib. Avoid coadministration of Sotorasib with proton pump inhibitors (PPIs), H2 receptor antagonists, and locally acting antacids. If coadministration with an acid-reducing agent cannot be avoided, administer Sotorasib 4 hours before or 10 hours after administration of a locally acting antacid

Sotorasib is a CYP3A4 substrate. Coadministration of Sotorasib with a strong CYP3A4 inducer decreased

• Sotorasib concentrations , which may reduce the efficacy of Sotorasib. Avoid coadministration of Sotorasib with strong CYP3A4 inducers

Sotorasib is a P-gp inhibitor. Coadministration of Sotorasib with a P-gp substrate increased its plasmaconcentrations, which may increase the adverse reactions of the substrate. Avoid coadministration of Sotorasib with P-gp substrates, for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the P-gp substrate dosage in accordance with its Prescribing Information.

Sotorasib is a BCRP-inhibitor. Coadministration of Sotorasib with a BCRP substrate increased its plasma

• concentrations, which may increase the risk of adverse reactions of the substrate. When coadministered with Sotorasib, monitor for adverse reactions of the BCRP substrate and decrease the BCRP substrate dosage in accordance with its Prescribing Information

Various FDA-approved generic manufacturers

It is not known if Sotorasib may harm your unborn baby. Talk to your healthcare provider about possible pregnancy and birth control choices that are right for you.

• Lumakras